KR102803917B1 - 루카파립의 고 용량 강도 정제 - Google Patents

루카파립의 고 용량 강도 정제 Download PDF

Info

Publication number
KR102803917B1
KR102803917B1 KR1020237020594A KR20237020594A KR102803917B1 KR 102803917 B1 KR102803917 B1 KR 102803917B1 KR 1020237020594 A KR1020237020594 A KR 1020237020594A KR 20237020594 A KR20237020594 A KR 20237020594A KR 102803917 B1 KR102803917 B1 KR 102803917B1
Authority
KR
South Korea
Prior art keywords
tablet
active ingredient
contained
range
pharmaceutically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237020594A
Other languages
English (en)
Korean (ko)
Other versions
KR20230097211A (ko
Inventor
제프리 에터
Original Assignee
파르마＆ 슈바이츠 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파르마＆ 슈바이츠 게엠베하 filed Critical 파르마＆ 슈바이츠 게엠베하
Publication of KR20230097211A publication Critical patent/KR20230097211A/ko
Application granted granted Critical
Publication of KR102803917B1 publication Critical patent/KR102803917B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020237020594A 2014-08-22 2015-08-17 루카파립의 고 용량 강도 정제 Active KR102803917B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462040849P 2014-08-22 2014-08-22
US62/040,849 2014-08-22
US201562101739P 2015-01-09 2015-01-09
US62/101,739 2015-01-09
KR1020177007284A KR20170043597A (ko) 2014-08-22 2015-08-17 루카파립의 고 용량 강도 정제
PCT/US2015/045522 WO2016028689A1 (en) 2014-08-22 2015-08-17 High dosage strength tablets of rucaparib

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177007284A Division KR20170043597A (ko) 2014-08-22 2015-08-17 루카파립의 고 용량 강도 정제

Publications (2)

Publication Number Publication Date
KR20230097211A KR20230097211A (ko) 2023-06-30
KR102803917B1 true KR102803917B1 (ko) 2025-05-07

Family

ID=55347324

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237020594A Active KR102803917B1 (ko) 2014-08-22 2015-08-17 루카파립의 고 용량 강도 정제
KR1020177007284A Ceased KR20170043597A (ko) 2014-08-22 2015-08-17 루카파립의 고 용량 강도 정제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177007284A Ceased KR20170043597A (ko) 2014-08-22 2015-08-17 루카파립의 고 용량 강도 정제

Country Status (19)

Country Link
US (3) US9987285B2 (enExample)
EP (1) EP3182975B1 (enExample)
JP (3) JP6574477B2 (enExample)
KR (2) KR102803917B1 (enExample)
CN (2) CN113209033A (enExample)
AU (2) AU2015305696B2 (enExample)
BR (1) BR112017000865A2 (enExample)
CA (1) CA2955495C (enExample)
DK (1) DK3182975T3 (enExample)
FI (1) FI3182975T3 (enExample)
IL (1) IL249946B (enExample)
LT (1) LT3182975T (enExample)
MX (1) MX367260B (enExample)
NZ (1) NZ728392A (enExample)
PT (1) PT3182975T (enExample)
RS (1) RS67356B1 (enExample)
RU (1) RU2705156C2 (enExample)
SG (1) SG11201700265VA (enExample)
WO (1) WO2016028689A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230107902A (ko) 2014-02-05 2023-07-18 머크 샤프 앤드 돔 엘엘씨 Cgrp-활성 화합물에 대한 정제 제제
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
RS67356B1 (sr) * 2014-08-22 2025-11-28 Pharma& Schweiz Gmbh Tablete rukapariba visoke doze
CN106008530B (zh) * 2016-07-24 2018-06-26 石家庄久正生物科技有限公司 一种抗卵巢癌药物Rucaparib关键中间体的制备方法
CN108201534A (zh) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种瑞卡帕布口服缓控释药物组合物及其用途
US10875870B2 (en) 2017-01-24 2020-12-29 Assia Chemical Industries Ltd. Solid state forms of rucaparib and of rucaparib salts
MX2019011496A (es) 2017-03-27 2020-01-23 Tesaro Inc Composiciones de niraparib.
BR112020006039A2 (pt) * 2017-09-26 2020-10-06 Tesaro, Inc. formulações de niraparibe
WO2019130229A1 (en) 2017-12-28 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing rucaparib
US10933069B2 (en) 2018-01-05 2021-03-02 Cybrexa 1, Inc. Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
CN109111454A (zh) * 2018-08-01 2019-01-01 宁波金未生物科技有限公司 一种瑞卡帕布s-樟脑磺酸盐
CN108853030B (zh) * 2018-09-26 2021-10-01 上海朝晖药业有限公司 一种治疗恶性肿瘤的药物制剂及其制备方法
WO2020113500A1 (zh) * 2018-12-06 2020-06-11 上海诚妙医药科技有限公司 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途
PH12022550037A1 (en) 2019-07-10 2023-04-12 Cybrexa 3 Inc Peptide conjugates of microtubule-targeting agents as therapeutics
EP3997093A1 (en) 2019-07-10 2022-05-18 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
ES3014370T3 (en) 2020-04-28 2025-04-22 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
EP4182318B1 (en) 2020-07-14 2025-08-27 Assia Chemical Industries Ltd. Solid state forms of rucaparib salts
AU2021319090A1 (en) 2020-07-29 2023-03-02 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
WO2022140537A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
AU2022255809A1 (en) 2021-04-08 2023-10-26 Incozen Therapeutics Pvt. Ltd. Inhibitors of poly(adp-ribose) polymerase
JP2024533756A (ja) 2021-09-27 2024-09-12 アラガン ファーマスーティカルズ インターナショナル リミテッド アトゲパントを含む片頭痛の併用療法
JP2024543323A (ja) * 2021-11-10 2024-11-21 クリチテック，インコーポレイテッド ルカパリブ粒子およびその使用
EP4463232A1 (en) 2022-01-11 2024-11-20 Assia Chemical Industries Ltd. Solid state forms of rucaparib tosylate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120302550A1 (en) * 2010-02-12 2012-11-29 Pfizer Inc. Salts and polymorphs of 8-fluoro-2--1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL210415B1 (pl) 1999-01-11 2012-01-31 Agouron Pharma Pochodne indolu, środek farmaceutyczny i zastosowanie pochodnych indolu
EP1611137A1 (en) 2003-03-31 2006-01-04 Pfizer Inc. Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
ATE454893T1 (de) 2003-07-25 2010-01-15 Cancer Rec Tech Ltd Tricyclische parp-hemmer
MX2007003311A (es) 2004-09-22 2007-05-16 Pfizer Procedimiento para preparar inhibidores de poli (adp-ribosa) polimerasas.
JP2008513435A (ja) 2004-09-22 2008-05-01 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤を含む治療用組成物
MX2007002461A (es) 2004-09-22 2008-03-13 Pfizer Formas polimorficas y amorfas de la sal fosfato de 8-fluoro-2-{4-[metilamino)metil]fenil}-1, 3, 4, 5-tetrahidro-6h-azepino [5, 4, 3-cd]indol-6-ona.
AU2009235426A1 (en) * 2008-04-09 2009-10-15 Lek Pharmaceuticals D.D. Granulation of active pharmaceutical ingredients
ES2654670T3 (es) 2012-04-05 2018-02-14 Vertex Pharmaceuticals Incorporated Compuestos útiles como inhibidores de la cinasa ATR y terapias de combinación de los mismos
RS67356B1 (sr) * 2014-08-22 2025-11-28 Pharma& Schweiz Gmbh Tablete rukapariba visoke doze

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120302550A1 (en) * 2010-02-12 2012-11-29 Pfizer Inc. Salts and polymorphs of 8-fluoro-2--1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one

Also Published As

Publication number Publication date
AU2015305696A1 (en) 2017-02-02
RU2705156C2 (ru) 2019-11-05
NZ728392A (en) 2023-06-30
JP2017525712A (ja) 2017-09-07
US20160051561A1 (en) 2016-02-25
AU2019272064B2 (en) 2021-11-18
SG11201700265VA (en) 2017-02-27
JP6797980B2 (ja) 2020-12-09
AU2015305696B2 (en) 2019-08-29
KR20230097211A (ko) 2023-06-30
EP3182975A1 (en) 2017-06-28
BR112017000865A2 (pt) 2017-12-05
RS67356B1 (sr) 2025-11-28
AU2019272064A1 (en) 2019-12-19
EP3182975A4 (en) 2018-04-18
RU2017109139A3 (enExample) 2019-03-06
KR20170043597A (ko) 2017-04-21
CA2955495A1 (en) 2016-02-25
DK3182975T3 (da) 2025-10-20
IL249946B (en) 2020-05-31
IL249946A0 (en) 2017-03-30
MX367260B (es) 2019-08-12
WO2016028689A1 (en) 2016-02-25
US20190099430A1 (en) 2019-04-04
JP2021038242A (ja) 2021-03-11
LT3182975T (lt) 2025-11-25
EP3182975B1 (en) 2025-10-01
FI3182975T3 (fi) 2025-11-13
MX2017001540A (es) 2017-05-11
JP7127101B2 (ja) 2022-08-29
JP2020002149A (ja) 2020-01-09
JP6574477B2 (ja) 2019-09-11
CA2955495C (en) 2023-09-19
CN106794185A (zh) 2017-05-31
CN113209033A (zh) 2021-08-06
US20180200260A1 (en) 2018-07-19
US9987285B2 (en) 2018-06-05
US10130636B2 (en) 2018-11-20
PT3182975T (pt) 2025-10-28
RU2017109139A (ru) 2018-09-24

Similar Documents

Publication Publication Date Title
KR102803917B1 (ko) 루카파립의 고 용량 강도 정제
KR100634253B1 (ko) 초강력 붕해제를 사용한 고속-용해 에파비렌즈 캡슐 또는정제 및 그의 제조 방법
CN102085201B (zh) 阿替洛尔和氨氯地平的双层片剂
EP3606511B1 (en) Pharmaceutical composition comprising lenvatinib mesylate
EP2197428B1 (en) Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof
EP1843754B1 (en) New pharmaceutical composition containing candesartan cilexetil as lipophilic crystalline substance
AU2018203007B2 (en) Ceritinib formulation
EP4436554A1 (en) Pharmaceutical compositions comprising eltrombopag
US20090215756A1 (en) Formulations containing losartan and/or its salts
KR20110104059A (ko) 경구 생체이용률이 낮은 화합물의 예비압축된 신속-붕해 제형
KR101944085B1 (ko) 발사르탄 함유 고형 경구제형 및 그 제조방법
HK1232807A1 (en) High dosage strength tablets of rucaparib
HK1232807B (en) High dosage strength tablets of rucaparib
JP2025524357A (ja) 多数の顆粒
KR20180060705A (ko) 에제티미브 및 로수바스타틴을 포함하는 경구용 복합정제
KR100822180B1 (ko) 마진돌 함유 정제의 안정화 방법
CA3150812A1 (en) Pharmaceutical formulations of indoleamine 2, 3-dioxygenase inhibitors
CN108721241A (zh) 一种包含缬沙坦和氨氯地平的固体组合物及其制备方法

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230619

Application number text: 1020177007284

Filing date: 20170316

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240226

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250225

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250429

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250430

End annual number: 3

Start annual number: 1

PG1601 Publication of registration